Drugs / Emactuzumab

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT03369964 Mar → Dec 2018 non-Hodgkin lymphoma Hoffmann-La Roche Withdrawn No outcome recorded
Phase 1 NCT02760797 May 2016 → Apr 2018 neoplasm Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT02323191 Jan 2015 → Aug 2020 Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT01494688 Dec 2011 → Feb 2018 cancer Hoffmann-La Roche Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02923739 May 2017 → Sep 2022 fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +10 M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 32 trials
Phase 3 NCT05417789 Oct 2024 → Dec 2025 overdue giant cell tumor of soft tissue SynOx Therapeutics Limited Active not recruiting No outcome recorded
Phase 3 NCT03768063 Feb 2019 → Jul 2028 expected cancer Hoffmann-La Roche Active not recruiting No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Emactuzumab Emactuzumab (RG7155) is a novel monoclonal antibody that inhibits CSF1R activation.” PMID 26179200 Jul 2015
6

NCT03369964

NCT02323191

NCT05417789

NCT03768063

NCT02760797

NCT02923739

Known as 7i1955n5wx ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370
Known as CXD-301 ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370
Known as RG-7155 ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370
Known as RO-5509554 ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370
Known as RO5509554 (ANTI-CSF-R1) ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370
Action Inhibit inhibits CSF1R activation” PMID 26179200 Jul 2015
Modality Monoclonal antibody “a humanised anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibodyPMID 33161240 Nov 2020
Route Intravenous “Patients received intravenous (IV) emactuzumab” PMID 33161240 Nov 2020
Target CSF1R “Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab” PMID 35577503 May 2022